In mid October 2015, Ab&B Bio was registered and established! In November 2015, the NDRC approved the project approval!

Ab&B Bio Settles in fertile land!

In February 2016, China Pharmaceutical City was officially signed.

On May 1, 2016, the land bidding, auction, and listing of the plot were successful.

On September 1st, 2016, the foundation stone laying ceremony for the commencement of the plot project was held.

In December 2016, the IND registration application for the Class I new biological product tetravalent influenza virus subunit vaccine was completed.

Ab&B Bio is working hard!

In January 2017, the new rabies vaccine project was signed.

In February 2017, the report on the qualification of the finished product of the tetravalent influenza virus subunit vaccine was obtained from the Chinese Academy of Inspection and Quarantine.

On August 1, 2017, the main body of the civil engineering project of the plot was successfully capped.

In November 2017, two clinical approvals were obtained for the formulation of a new class I biological product tetravalent influenza virus subunit vaccine for children and adults.

In December 2017, the new rabies vaccine project was launched.

Ab&B Bio Dream sets sail!

In April 2018, the construction of the tetravalent influenza virus subunit vaccine stock solution and preparation workshop on Plot 1 was started.

In December 2018, the optimization and amplification of the tetravalent influenza virus subunit vaccine process and the preparation of phase I clinical samples were completed.

In December 2018, the A-round financing was successful, and Shenzhen Gaotejia Investment Group led the investment of 100 million yuan, boosting the launch of Zhonghui Biological Dream.

In December 2018, the plant construction was fully completed.

Ab&B Bio Goes Together!

In February 2019, the clinical protocol formulation and ethical committee approval of the tetravalent influenza virus subunit vaccine were completed.

In August 2019, the phase I clinical launch of the tetravalent influenza virus subunit vaccine was carried out.

In September 2019, workshop validation was completed, and process transfer, process amplification, and commercial batch production process validation were carried out.

In November 2019, the Phase I clinical field work of the tetravalent influenza virus subunit vaccine was completed.

In November 2019, he obtained a drug production license.

In December 2019, the preparation of phase III clinical samples of the tetravalent influenza virus subunit vaccine was completed.

Ab&B Bio creatures seize every day!

In January 2020, the production process validation of commercial batches of tetravalent influenza virus subunit vaccine preparations was completed.

In May 2020, the joint application for the registration of the biological product class I new drug recombinant herpes zoster vaccine (CHO cell) project was successful.

In May 2020, the joint application for the biological product class I new drug nine-valent recombinant human papillomavirus vaccine (Pichia pastoris) project was successfully registered.

In May 2020, the phase III clinical trial of the tetravalent influenza virus subunit vaccine was launched.

On May 23, 2020, the contract for pneumococcal polysaccharide vaccine was successfully signed.

In July 2020, we obtained clinical approval documents for a new class of biological products, recombinant herpes zoster vaccine (CHO cell), and 9-valent recombinant human papillomavirus vaccine (Pichia pastoris).

In August 2020, the phase III clinical field work of the tetravalent influenza virus subunit vaccine was completed.

On September 23, 2020, the phase I clinical trial of pneumococcal polysaccharide vaccine was carried out.